BOIRON Report issue

For profit Phase 3
Founded: Lyon France (2003)
Status: Left NME R&D (2009)

Organization Overview

First Clinical Trial
2009
NCT01066741
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

gelsemium sempervirens (1 trial)

sodium bicarbonate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 3)

Mucositis (Phase 3)

Oropharyngeal Neoplasms (Phase 3)

Stomatitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2